Relief Therapeutics Holding AG (RLFTF)

[pegs1]

Penny World
Can you give me an update on aviptadil? Are they planning clinical trials this year for sarcoidosis? I didn't qualify for the Atyr Pharmaceuticals clinical trial. My forced vital capacity lung test was low. They wanted it at 50 & mine was at 40. I'll find out on Monday if I qualify for another clinical trial with Kinevant Therapeutics. But I feel that I won't qualify for it either. I saw the physician heading that trial yesterday. He wants to start me on a biologic (remicade). At this point I'll try anything! I'm hoping that maybe he can help me to get kinevant through expanded access. My own pulmonologist will not apply for expanded access of kinevant! He told me that he didn't feel comfortable prescribing a non-fda approved drug! I angrily told him that everything he has given me hasn't worked! That I'm going to die! He told me that he took an oath to do no harm. That he would do everything to prevent me from dieing. I don't believe him. He has exhausted all medications to treat me. I'm sorry for venting. I've been checking clinical trials.gov frequently. But I didn't see any trial for aviptadil. Any news is greatly appreciated.........

[PennyWorld]

As part of the FDA's Coronavirus Treatment Acceleration Program, Relief Therapeutics, a Swiss company, is examining the effectiveness of Aviptadil, a patented synthetic version of a human vasoactive intestinal polypeptide (VIP), for COVID-19-related ARDS at New York University Langone (NYU Langone Health) (CTAP).

Do a find on : "Relief"
https://www.bloomberg.com/press-releases/2023-01-31/at-7-5-cagr-global-peptide-synthesis-market-size-share-to-surpass-us-845-68-million-by-2028-peptide-synthesis-industry

[theswordman]

https://pharmaceutical-journal.com/article/feature/everything-you-need-to-know-about-the-covid-19-therapy-trials

[rollup]

For our (Bullish) friends in the USA, latest presentation of AVIPTADIL (name in India Oxyptadil) by Zuventus India - the train is rolling....

insert-text-here

[Joe Kaplan]

Thanks, Great Link panton.
Seems for a biotech, only a few times sales is pretty minimal, and
thats another reason to consider a substantial percentage increase in the longer run.

And with covid and all the other possibilities......tremendous potential.

A safe effective wonder drug, IMHO.

[panton]

Hi Joe. The info you’re looking for can be found on Reliefs website. Here’s the link.

https://www.relieftherapeutics.com/images/vL_Relief_Therapeutics_Valuation_Report_27DEC22.pdf

[Joe Kaplan]

Excellent, excellent News, thanks Panton for the info on the RLF cancer med TD 011.
With a north american market value projected at over half a billion by 2028, it might be interesting
to speculate on the GLOBAL market value at that time or for this year. .
And thats not to mention other potential cancer applications for Relief Therapeutics.

Please refresh my thoughts on market value projections for CIP, ARDS or Sarcoidosis.

[panton]

GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), a biopharmaceutical company identifying, developing and commercializing novel, patent protected products in select specialty, rare and ultra-rare disease areas, announced independent institutional review board (IRB) approval for the protocol of an investigator-initiated trial to evaluate RLF-TD011 as an adjunctive treatment for patients diagnosed with cutaneous t-cell lymphoma (CTCL). The study will evaluate the effect of RLF-TD011, a patent-protected hypochlorous acid topical spray, on the microbiome of CTCL skin lesions and determine tolerability, symptom improvement, and potential for reducing lesion size and skin disease activity.

Relief Therapeutics Holdings AG, Tuesday, December 27, 2022, Press release picture
Relief Therapeutics Holdings AG, Tuesday, December 27, 2022, Press release picture
The study will enroll participants at Northwestern department of dermatology in Chicago. Microbiome assessments will be performed under the leadership of co-principal investigator Alan Zhou, M.D., MSc., fellow of the American Academy of Dermatology and assistant professor of dermatology at Northwestern University.

CTCL is a rare, heterogeneous group of non-Hodgkin's lymphomas in which malignant t-cells infiltrate the skin. Advanced CTCL lesions harbor Staphylococcus aureus, which release toxins that stimulate malignant cells and drive disease progression. This often leads to recurrent skin infections with a high risk for sepsis and death.

"Treatment of advanced CTCL remains a challenge, with five-year disease-specific survival rates ranging from 70 percent for early stage to 24 percent for advanced disease, with the greatest mortality stemming from bacterial infections," said Dr. Alan Zhou. "This proof-of-concept clinical study will look at the microbiome changes and clinical improvement in 30 patients over an eight-week study period. We will evaluate how the bactericidal activity of this unique hypochlorous acid skin spray, previously shown to kill methicillin-sensitive and methicillin-resistant Staphylococcus aureus, as well as Pseudomonas aeruginosa-could improve the CTCL microbiome to potentially decrease pruritus, erythema, scaling, lesion size and overall skin disease activity, with the goal of delaying disease progression and reducing death."

"This investigator-initiated trial represents an important step in the clinical development pathway of RLF-TD011," said Nermeen Varawalla, M.D., D.Phil., M.B.A., chief medical officer, Relief Therapeutics. "Data from this study will be utilized to facilitate the design and conduct of follow-on, multi-center, pivotal clinical trials, which will potentially serve as the clinical support for our eventual submissions to the U.S. Food and Drug Administration and European Medicines Agency for RLF-TD011 as an effective, convenient and well-tolerated treatment for CTCL, thereby addressing an important unmet medical need in an intractable, incurable disease."

ABOUT CUTANEOUS T-CELL LYMPHOMAS

Cutaneous t-cell lymphomas (CTCLs) are a rare group of disorders known as non-Hodgkin's lymphomas characterized by abnormal accumulation of malignant t-cells in the skin that can result in the development of rashes, plaques and tumors. Because CTCL is rare and often looks like eczema or another common skin disease, it can be difficult to diagnose. While there are many types of CTCLs, the most common diagnoses are mycosis fungoides, primary CTCL and primary cutaneous anaplastic large cell lymphoma[1]. The overall incidence rate of CTCL was 8.55 per 1 million with MF being the subtype with the highest incidence, at 5.42 per 1 million[2]. The overall incidence of CTCL in the U.S. and Europe has increased, a reflection of better diagnostic tools and increased awareness among physicians and patients, which has led to improved disease detection[3].

According to Fortune Business Insights, the North American CTCL therapeutics market size is projected to hit an annual valuation of USD $587.4 million by 2028, registering a 13.6 percent compound annual growth rate (CAGR) in the 2021-2028 period[4]. The market value was estimated to be worth USD $225.9 million in 2020 and reached USD $240.9 million in 2021. The increasing burden of CTCL in the region is slated to increase the demand for novel CTCL therapeutics solutions. Cleveland Clinic reports that more than 3,000 new CTCL patients are diagnosed in the U.S. each year and about 16,000-20,000 individuals suffer from mycosis fungoides, the most common form of CTCL that is linked to skin-localized immune cell stimulation.

ABOUT RLF-TD011

RLF-TD011 was developed using the TEHCLO® proprietary technology and is a highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), with pH between 2.5 - 3.0 and high reduction-oxidation potential (ORP 1.000 - 1.200 mV). It is a self-administered, sprayable solution enabling targeted application while avoiding skin contact and cross-contamination. RLF-TD011 has consistently been shown to accelerate wound closure with reduced infection rates in clinical trials[5],[6],[7]. If approved in this indication, it will be the first product specifically indicated to improve the microbiome in CTCL resulting in symptom control and halting disease progression.

RLF-TD011 is currently registered under the brand name Nexodyn® AcidOxidizing Solution (AOS) for use in the debridement, irrigation, cleansing and moistening of chronic wounds and acute wounds, post-surgical wounds, cuts, abrasions, burns and other lesions. Nexodyn AOS is certified in the EU as class III medical device and in the U.S., as a 510(k) cleared unclassified device.

ABOUT RELIEF THERAPEUTICS Holding SA

Relief Therapeutics is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases and connective tissue disorders. Relief Therapeutic's diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, engineered with the proprietary Physiomimic™ technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria (PKU). Relief Therapeutics has a collaboration and license agreement with Acer Therapeutics for the worldwide development and commercialization of Olpruva™ (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and maple syrup urine disease (MSUD). Relief Therapeutics also continues to develop aviptadil for several rare pulmonary indications. Further, Relief Therapeutics is undertaking the clinical development of RLF-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa (EB), a group of rare, genetic, life-threatening connective tissue disorders; RLF-TD011 has been granted orphan drug designation by the U.S. FDA. Finally, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.

For more information, please visit www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn and Twitter.

FOR MEDIA/INVESTOR INQUIRIES CONTACT:

RELIEF THERAPEUTICS Holding SA
Catherine Day
Vice President, IR & Communications
[e-mail]

LifeSci Advisors
Irina Koffler
[phone]
[e-mail]

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether the study described above will be successful (ii) whether APR-TD011 (Nexodyn™ AOS) will ever be approved in the U.S., the U.K., or the E.U. for the treatment of EB or any other disease, and (iii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX and with the U.S. Securities and Exchange Commission, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

[1] https://www.aad.org/public/diseases/skin-cancer/types/common/ctcl/symptoms

[2] Cai ZR, Chen ML, Weinstock MA, Kim YH, Novoa RA, Linos E. Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis. JAMA Oncol. 2022;8(11):1690-1692. doi:10.1001/jamaoncol.2022.3236

[3] Cai ZR, Chen ML, Weinstock MA, Kim YH, Novoa RA, Linos E. Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis. JAMA Oncol. 2022;8(11):1690-1692. doi:10.1001/jamaoncol.2022.3236

[4] Fortune Business Insights (https://www.globenewswire.com/en/news-release/2022/02/16/2385997/0/en/North-America-Cutaneous-T-Cell-Lymphoma-CTCL-Therapeutics-Market-Size-2022-2028-to-Reach-USD-587-4-Million-at-a-CAGR-13-6.html)

[5] Iacopi E. et al. The Use of a Novel Super-Oxidized Solution on Top of Standard Treatment in the Home Care Management of Postsurgical Lesions of the Diabetic Foot Reduces Reinfections and Shortens Healing Time. Int J Low Extrem Wounds. 2018 Dec; 17(4):268-274

[6] Strohal R, et al. The management of critically colonized and locally infected leg ulcers with an Acid-Oxidizing Solution: A pilot study. Adv Skin Wound Care 31(4):163-171, 2018.

[7] Ricci E, et al. The management of chronic ulcers with an AcidOxidizing Solution. J Wound Care 25(8):443-50, 2016.

SOURCE: Relief Therapeutics Holdings AG



View source version on accesswire.com:
https://www.accesswire.com/735485/Relief-Therapeutics-Announces-IRB-Approval-of-Investigator-Initiated-Trial-Evaluating-RLF-TD011-as-an-Adjunctive-Treatment-for-Cutaneous-T-Cell-Lymphom

[PennyWorld]

I noticed this on the YF board. Assessment by the "Valuation Lab"

I like this Valuation Lab observation: "Relief is developing a diversified product portfolio in rare metabolic, pulmonary, and connective tissue disorders, all with high margins. The recent US launch of PKU GOLIKE and the approval and future launch of ACER-001 should provide a boost to short and medium-term revenues. The successful development of RLF-100 in rare pulmonary disorders such as pulmonary sarcoidosis and acute respiratory distress syndrome (ARDS), RLF-TD011 in epidermolysis bullosa (EB), and RLF-OD032 in PKU should boost medium and long-term revenues substantially."

[Joe Kaplan]

Thanks PW. Also....things are progressing as can be viewed in the link.
Never as quickly as I would like however. :)

https://www.relieftherapeutics.com/pipeline

[PennyWorld]

Patience is a Virtue! ACER just won FDA approval on ACER-001, which will generate a new revenue stream for RLFTF.
**
The companies will split net profits from Acer’s territories 60%:40% in favor of Relief. In addition, Relief has licensed the rights for the rest of the world, where Acer will receive from Relief a 15% royalty on all revenues received in Relief’s territories. Acer may also receive a total of $6 million in development milestone payments following the first European (EU) marketing approvals for UCDs and MSUD.

[gmoney909]

I just look at this daily and see no movement -- maybe you should stop fooling yourself and also accept your loses --

[theswordman]

link for youtube video--Dr. Agam Vora-Mumbai. The avip part @ 13 mins. The first 12 mins is about ARDS--good info. Good video

[turbo996]

Put https://

[turbo996]

youtube.com/watch?v=a5iUC3pD2Pw&feature=shares

[turbo996]

Trouble posting address

[turbo996]

Spam here. Ignore this.

[Joe Kaplan]

G....you say you have moved on..
Obviously you have not.
You are still back here, and have NOT moved on and have NOT accepted your losses.

Good Luck. I hope you "move on" like you claim.

[gmoney909]

This scam cant get past 3 cents - accept your loses and move on -- I did

[PennyWorld]

panton...Let's hope that somebody at RLFTF knows something about generating revenues! Thus far they have been very good at dilution by dumping shares on the open market to pay their salaries. Now they have no excuse for not putting the sales people to work to try and sell a product. US launch of Olpruva (ACER-001) in UCDs (early 2023)

[panton]

PW. Let’s up the catalysts can offset further dilution but you could be right again. And thanks for making those calls!

A cash position of CHF 29.9 mn (30 June 2022) provides a cash runway through Q3 2023. We estimate an additional CHF 30 mn funding is required to reach the targeted breakeven in late 2024. We derive a sum-of-parts rNPV of CHF 0.329 per share, based on 5,416 mn shares (23% share dilution) to account for the CHF 30 mn funding gap, and qualify the risk profile as Speculative with no substantial revenues, yet.
Key catalysts:
1) US launch of Olpruva (ACER-001) in UCDs (early 2023): branded “Olpruva” by
Acer in the US, adds another high-priced, high-margin, rare disease product to
Relief’s revenue stream, which can be marketed through a small specialist sales force
2) EUfilingofOlpruva/ACER-001inUCDs(early2023):submissionoftheMarketing
Authorization Application (MAA) for potential EU approval in UCDs in 2024
3) RLF-100INHALED“LeuppiStudy”toplineresults(Q12023):inthepreventionof COVID-19; these trial results, together with the NRx clinical data package, will
determine the future development of RLF-100 in potential COVID-19 indications

[panton]

PW. You could be right and we might have to eventually convert. The way I came up with my conclusion is Relief is referring to RLFTF as ordinary shares and not ADS.

Our ordinary shares are listed on the SIX Swiss Exchange under the symbol “RLF”. Our ordinary shares also currently trade on the over-the-counter market under the symbol “RLFTF” and our ADSs currently trade on the over-the-counter market under the symbol “RLFTD”. We have applied to list our ADSs on the Nasdaq Global Market, under the symbol “RLFT”

[PennyWorld]

Another issue that I have relates to RAM diluting by dumping (selling) ADRs. When that starts to happen in a large way (which I'm sure it will), then it would seem to me that the dilution on the EPS ratio at the ADR level will directly impact the EPS ratio on the underlying RLFTF OTC shares. So dilution in one effectively dilutes the other on the balance sheets. I think RAM is simply using smoke and mirrors, and his longer term goal is to raise cash by dilution of ADRs. Why he hasn't been able to persuade the board to r/s RLFTF puzzles me. Possibly GEM vetoed the r/s as an option. Too bad that we don't have a bionic fly sitting on the wall during the board meetings.

[PennyWorld]

panton.. i've read this before. But the problem is that item 1 on your list only refers to RLF shares on the Swiss. It does not refer to the RLFTF on the OTC. I have a strong feeling that after the ADRs get uplisted to the NASDAQ that the RLFTF shares on the OTC will be dead wood (not tradable), unless I proactively convert my shares. I'm going to make more phone calls next week. This week it seems everyone is out of the office for the holidays.

[turbo996]

If the uplisted stock RLFTY starts making gains over and above RLFTF then I will voluntarily pay my 500 bucks and convert but if I have the choice, I will wait and see

[panton]

I haven’t spoken to anyone and my findings are what is available on their website but if I’m correct, there’s nothing, (providing we want to remain ordinary shareholders and not convert to ADS), that we need to do. It appears that the ADS is solely a new offering and is addition to current ordinary shares. I own RLFTF and believe I can continue to hold without any conversion. Of course, all this can change in a heartbeat.

1) From Reliefs website…
Do I have to convert my Ordinary Shares into ADSs?
No, the Company’s Ordinary Shares continue to trade on the SIX Exchange in Switzerland. If you do not wish to hold ADSs but wish to remain a holder of Relief Therapeutics Ordinary Shares then no action is required.

2) This newsletter seems to only impact ADR…..

GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), announced today that it has filed Amendment No. 2 to its Form F-6 registration statement for depositary shares evidenced by American Depositary Receipt ("ADR") with the U.S. Securities and Exchange Commission ("SEC"). The amendment was filed to reverse split and change the ratio of Relief's ADRs to Relief's ordinary shares from 1 to 150 to 1 to 200. The new ratio will take effect on November 3, 2022. The reverse split and ratio change is being undertaken as part of Relief's plan to prepare for an uplist of its ADRs to the NASDAQ Stock Market.
Relief's ADRs are currently traded on the over-the-counter ("OTC") under the trading symbol ("RLFTY").

3) New offering….
December 27, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), announced today that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed offering of its ordinary shares in the form of American Depositary Shares (ADSs). The preliminary prospectus provides for the possible sale of 833,333,200 ordinary shares in the form of ADSs (4,166,666 ADSs) in the United States and warrants to purchase 625,000,000 ordinary shares in the form ADSs (3,125,000 ADSs). In addition, the preliminary prospectus sets forth that Relief will grant the underwriters an option to purchase up to an additional 125,000,000 ordinary shares in the form of ADSs (625,000 ADSs) and additional warrants to purchase up to 93,750,000 additional shares in the form of ADSs (468,750 ADSs). The number of ADSs to be offered and the price range remain subject to change, and there can be no assurance that the offering contemplated by the registration statement will be completed. Relief will report the final terms of the contemplated offering once fixed in a future amendment to its registration statement. The offering, if made, will only be made by means of an effective prospectus. Further information is available in the Amendment No. 2 here .

[PennyWorld]

I have three questions I'm trying to get answered (for those own RLFTF on the OTC):

1) will there be a forced conversion to ADRs on us?
2) will there be a point in time whereby if we don't convert that we will not be able to trade our OTC shares
3) what impact will the ADR conversion (1 for 200 reverse split) have on the underlying 'unconverted' OTC shares?

[turbo996]

I haven't heard anything definite or concrete. I've heard what we all heard about uplisting but at this point, it is supposition. Reverse splits are never good but this one is pinned to the SIX so we shall see how this goes.

[PennyWorld]

I haven't been able to find any information on this topic as it relates to SH who own RLFTF shares on the OTC. Have you? I've tried reaching JP Morgan, and no one picks up the phone.

[gmoney909]

Is this scam still trading ?

[turbo996]

That info is for SIX listed shares if I read this correctly

[threebabiesbusy]

I’ve never held ADR’s so not familiar with them.

[threebabiesbusy]

Thanks Bob. Is either one better or have advantage that other doesn’t?

[Bob1968]

More info:
https://relieftherapeutics.com/images/Instructions-for-Converting-Relief-Therapeutics-ORDs-to-ADRs-FINAL

Do I have to convert my Ordinary Shares into ADSs?
No, the Company’s Ordinary Shares will continue to trade on the SIX Exchange in
Switzerland. If you do not wish to hold ADSs but wish to remain a holder of Relief
Therapeutics Ordinary Shares then no action is required.

[threebabiesbusy]

What do we do if still holding original rlftf shares….in US. Haven’t converted to ADR’s

[turbo996]

https://www.renaissancecapital.com/IPO-Center/News/96550/Swiss-rare-disease-biopharma-Relief-Therapeutics-sets-terms-for-$25-million

[panton]

From Reliefs website regarding initial public offering of ADS shares.


https://www.sec.gov/Archives/edgar/data/1854078/000119312522311696/d399582df1a.htm

in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED DECEMBER 23, 2022
PRELIMINARY PROSPECTUS
4,166,666 Units Consisting of
4,166,666 American Depositary Shares
Representing 833,333,200 Ordinary Shares
and Warrants to Purchase up to 3,125,000 American Depositary Shares

This is the initial public offering of our American Depositary Shares, or ADSs. Each ADS represents the right to receive 200 ordinary shares and the ADSs may be evidenced by American Depositary Receipts, or ADRs. We are selling (i) 833,333,200 ordinary shares in the form of ADSs in the United States (the “Shares”), and (ii) warrants to purchase 625,000,000 ordinary shares in the form ADSs (the “Warrants”). The Shares and accompanying Warrants will be sold in Units (each, a “Unit”), with each Unit consisting of one Share and one Warrant to purchase 0.75 of an ADS. Each whole Warrant is exercisable to purchase one ADS (each, a “Warrant Share”) at an assumed exercise price of $

(120% of the public offering price per unit), will be exercisable upon issuance and will expire five years from the date of issuance. This prospectus also relates to the offering of the Warrant Shares issuable upon exercise of the Warrants. The Shares and Warrants will be immediately separable upon issuance. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities.
Our ordinary shares are listed on the SIX Swiss Exchange under the symbol “RLF”. Our ordinary shares also currently trade on the over-the-counter market under the symbol “RLFTF” and our ADSs currently trade on the over-the-counter market under the symbol “RLFTD”. We have applied to list our ADSs on the Nasdaq Global Market, under the symbol “RLFT”. There can be no assurance that, even if our listing is successful, that an active trading market for our ADSs will develop or be sustained. On December 19, 2022, the last reported sale price of our ordinary shares on the SIX Swiss Exchange was 0.0288 CHF per common share, equivalent to a price of $6.20 per ADS as calculated by the official exchange rate on such date.
We estimate that the offering price per Unit will be between $5.50 and $6.50, determined by reference to the prevailing market prices of our ordinary shares on the SIX Swiss Exchange, after taking into account market conditions and other factors
There is no established public trading market for the Warrants, and we do not expect such a market to develop. We do not intend to apply for the listing of the Warrants on any national securities exchange. Without an active trading market, the liquidity of the Warrants will be limited.


We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012, and, as such, have elected to comply with certain reduced public company reporting requirements.

[PennyWorld]

Acer wins FDA OK for Olpruva to treat urea cycle disorders
Dec. 23, 2022 2:30 PM ETAcer Therapeutics Inc. (ACER), RLFTF, RLFTYBy: Dulan Lokuwithana, SA News Editor
Headquarters of US Food and Drug Administration (FDA)
Grandbrothers/iStock Editorial via Getty Images

The U.S. Food and Drug Administration (FDA) has greenlighted Olpruva, being developed by Acer Therapeutics (NASDAQ:ACER) and Swiss biotech Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) as a treatment for patients with urea cycle disorders (UCD).

The oral treatment, also known as sodium phenylbutyrate, will therefore be indicated in the U.S. as an adjunctive therapy to the standard of care for chronic management of adults and children with UCDs.

UCDs are a genetically-driven group of diseases that impact the urea cycle, leading to excess accumulation of blood ammonia, which can result in lethargy, coma, multi-organ failure, seizures, and psychiatric symptoms.

In June 2022, the FDA rejected the therapy citing the need for an adequate review of Acer's (ACER) third-party contract manufacturer for the drug, then known as ACER-001.

However, the following month, FDA accepted the company's resubmitted New Drug Application for ACER-001, issuing Jan. 15, 2023, as the target action date.

In August, Acer (ACER) and Relief (OTCQB:RLFTF) announced the European orphan medicinal product designation for ACER-001 as a treatment for the rare metabolic disorder Maple Syrup Urine Disease.

[PennyWorld]

This is encouraging.....RLFTF will receive profits from this drug if it is approved.
https://industrytrend.net/2022/acer-acer-therapeutics-acer-001-to-be-approved-by-fda/

[PennyWorld]

Great News...
https://relieftherapeutics.com/newsblog-detail/?newsID=2408385

[PennyWorld]

Well, it looks like the case between RLFTF and NRX is over. I'm assuming that now the IP and trial data will be handed over to RLTF. But Dr JJ is not yet off the hook!

https://investorshub.advfn.com/uimage/uploads/2022/12/19/ixjytRLFTF_Case_Update.jpg

[Joe Kaplan]

A worthwhile source of info on occasion.

https://twitter.com/search?q=Relief%20Therapeutics&src=typed_query&f=live

Thanks for all that post and share.

[PennyWorld]

ACER is on another run again (up 45%). If the the Jan 15 PDUFA is a success, that means some nice future revenues for RLFTF !

[longtrailer]

Thanks for sharing this information detailing what Relief can gain from ACER 001 revenues with FDA approval.

[PennyWorld]

panton...nice profit deal recap!

[panton]

Share in the profits they will! Could also be the reason why Relief just named Jack Weinstein as the CEO.

Relief has agreed to pay up to $20 million in U.S. development and commercial launch costs for the Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD) indications. Acer will retain development and commercialization rights in the U.S., Canada, Brazil, Turkey and Japan. The companies will split net profits from Acer’s territories 60:40 in favor of Relief. In addition, Relief has licensed the rights for the rest of the world, where Acer will receive from Relief a 15% royalty on all net sales and other revenues received in Relief’s territories. Acer may also receive a total of $6 million in development milestone payments following the first European (EU) marketing approvals for UCDs and MSUD.

[PennyWorld]

ACER is on a 'run'. Remember....RLFTF receives a chunk of the profits from the sale of ACER-001.

PDUFA date is January 15, 2023.

Good PR out on this.
https://finance.yahoo.com/news/2-biotech-stocks-under-10-023527396.html

[panton]

PW. I’m in the same boat as you and agree with your assessment. Joe, from Relief’s website, it appears JP Morgan is handling the conversion. It might be helpful if you call them directly—number listed below…

Instructions for Converting Relief Therapeutics SIX-
Listed Ordinary Shares into ADSs
This information is intended to guide holders of Ordinary Shares, which are admitted to trading on Switzerland’s SIX exchange, through the process of exchanging Ordinary Shares for ADSs and to answer certain related frequently asked questions applicable to holders of the Ordinary Shares.
For any further questions about the Ordinary Share to ADS conversion process, please contact the Company's ADS depositary bank, J.P. Morgan Chase Bank, at [e-mail], settlements hotline: [phone].
What are American Depositary Shares (ADSs)?
ADSs are shares issued by a US depositary bank and are traded by investors on a US-based stock market. Holders of a company’s Ordinary Shares traded on non-US exchanges deposit their shares with the US depositary bank, which then issues ADSs that are tradable in the US. In the case of Relief Therapeutics’ ADSs, each ADS represents 200 of the Company’s Ordinary Shares – i.e., one ADS is issued for every 200 Relief Therapeutics shares deposited with J.P. Morgan.
How does the price of Relief Therapeutics’ ADSs compare to the price of an Ordinary Share in Switzerland?
Each Relief Therapeutics ADS represent 200 Ordinary Shares. The price of each ADS is expressed in US dollars and the value of each ADS is expected to be associated with the value of the 200 Ordinary Shares that it represents.
What does it cost to convert Ordinary Shares into ADSs?
There will be an issuance fee of up to US$5.00 per 100 ADSs (or portion thereof) charged by J.P. Morgan for the issue of the ADSs. The exchange of your dematerialised Ordinary Shares will need to be managed by your broker as Ordinary Shares need to be transferred electronically to J.P. Morgan prior to the issuance of ADSs. Your selected broker may also levy an administrative charge for managing the exchange process.
1

How long does it take and is dematerialisation necessary?
J.P. Morgan typically can be expected to deliver ADSs to your broker within two business days of receiving an electronic transfer of Ordinary Shares from your broker. However, before this can happen, if you hold your Ordinary Shares in certificated form you will need to send your share certificate and a signed stock deposit form to your broker who will then need to manage the “dematerialisation” process needed to exchange your shares into electronic form. The timescale for this will depend on your broker but should be expected to take about a week.
I don’t have a broker – do I really need one?
Yes, exchange into ADSs will require the assistance of a broker.
Is there a cost to hold ADSs?
J.P. Morgan may charge an annual Depositary Service Fee of up to US$0.05 per ADS. This is typically collected from the broker or other intermediary that holds the ADSs on your behalf. Your broker may pass this fee on to you directly or it may be part of the annual fee that you pay to maintain your brokerage account.
Do I have to convert my Ordinary Shares into ADSs?
No, the Company’s Ordinary Shares continue to trade on the SIX Exchange in Switzerland. If you do not wish to hold ADSs but wish to remain a holder of Relief Therapeutics Ordinary Shares then no action is required.
Are all Ordinary Shares eligible to be deposited for delivery of ADSs?
No. Ordinary Shares that are owned by a director or other person that may be considered an “affiliate” of the Company under U.S. securities law, and Ordinary Shares that were received in a private placement and have been held for less than a year, are generally not eligible to be deposited.
2

Process for exchanging Ordinary Shares into ADSs:
Step 1: Select a broker with US listed securities trading capability. If you do not already have an account with a broker, you may be able to open one either online or through banks and other intermediaries which offer brokerage services. You need to ensure that the broker and type of account on offer is capable of holding and trading US listed securities. Please ensure that you check with your broker that they can hold Relief Therapeutics ADSs and have a DTC (a member of the U.S. Federal Reserve System, a limited-purpose trust company under New York State banking law and a registered clearing agency with the U.S. Securities and Exchange Commission) participant account.
Step 2: You will need to contact your broker and ask them how to transfer your existing Ordinary Shares into your account. If you hold physical share certificates you will need to send them, together with a completed stock deposit form, to your broker. The broker must provide you with the required stock deposit form and instructions. When the broker receives the share certificates, they will need to “dematerialise” the shares into electronic form so that they are held electronically by the broker. When completed, your broker can then deal with the conversion into ADSs. If you already hold your Ordinary Shares in dematerialised form, you can arrange for these to be delivered to the broker handling the ADS conversion.
Step 3: Your broker will need to contact J.P. Morgan by email to arrange for the conversion of your Ordinary Shares into ADSs. You will receive one ADS for every 200 Ordinary Shares that you hold and choose to convert. J.P. Morgan can be contacted using the following contact details: [e-mail], settlements hotline: [phone].

[PennyWorld]

Joe, it's my understanding that the R/S only impacts you if you own ADRs. I never bought any, nor have I converted my RLFTF OTC shares to ADRs. I'm still waiting for RLFTF to 'force' me to convert my OTC shares to ADRs.

What's not clear to me is what impact will the ADR R/S have on the price of RLFTF. I suspect none. But I could be wrong. This whole ADR initiative is weird stuff that RAM is doing, and he doesn't communicate the mechanics of his intent to the SH. Other than his goal is to eventually convert all RLFTF shares to ADRs. I'm holding my breath on that one.

Hopefully someone else here who is 'in the know' on the ADRs can post on this topic.

[Joe Kaplan]

PW....After talking to several brokers at one of my accounts, it seems they have little information about the up coming 200 for 1 reverse split.
Do you have any info you could update us on as far as time frames and or costs to move into the new stock on the nazdaq. ? TIA.